Shintaro Takao

Kobe, 6580064, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Targeted axillary dissection using CT-Lymphography and the tattooing technique after neoadjuvant chemotherapy for node-positive breast cancer.

Targeted axillary dissection using CT-Lymphography and the tattooing technique after neoadjuvant chemotherapy for node-positive breast cancer.

Journal: International cancer conference journal

Published: February 08, 2026

Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.

Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.

Journal: Breast cancer research : BCR

Published: February 02, 2026

Co-occurrence of breast cancer and malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1.

Co-occurrence of breast cancer and malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1.

Journal: International cancer conference journal

Published: September 26, 2024

Eribulin induces micronuclei and enhances the nuclear localization of cGAS in triple-negative breast cancer cells.

Eribulin induces micronuclei and enhances the nuclear localization of cGAS in triple-negative breast cancer cells.

Journal: Research square

Published: December 18, 2023

Eribulin induces micronuclei and enhances the nuclear localization of cGAS in triple-negative breast cancer cells.

Eribulin induces micronuclei and enhances the nuclear localization of cGAS in triple-negative breast cancer cells.

Journal: Scientific reports

Published: November 27, 2023

Feasibility Study of Transarterial Chemotherapy Followed by Chemoembolization for Recurrent Breast Cancer.

Feasibility Study of Transarterial Chemotherapy Followed by Chemoembolization for Recurrent Breast Cancer.

Journal: Journal of vascular and interventional radiology : JVIR

Published: January 18, 2023

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).

Journal: International journal of clinical oncology

Published: September 27, 2022

Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).

Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).

Journal: Breast cancer (Tokyo, Japan)

Published: September 24, 2022

Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.

Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 20, 2022

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.

Journal: PloS one

Published: May 26, 2022

Correction to: Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.

Correction to: Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.

Journal: Breast cancer (Tokyo, Japan)

Published: May 02, 2022

Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.

Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.

Journal: Journal of bone and mineral metabolism

Published: March 01, 2022

Showing 1-12 of 50

Last Updated: 09/26/2026